AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Harmony Biosciences to Extend Pitolisant Exclusivity to 2044 with New Orexin Agonist
ByAinvest
Tuesday, Dec 2, 2025 9:33 pm ET1min read
Harmony Biosciences Holdings reported positive bioequivalence results for its gastro-resistant pitolisant formulation and began a Phase 1 trial of an investigational orexin 2 receptor agonist for central disorders of hypersomnolence. This could extend pitolisant-related exclusivity towards 2044 and add a new mechanism in orexin agonism, deepening Harmony's sleep-disorder treatment portfolio. The pivotal bioequivalence success for pitolisant GR is a key near-term catalyst, but the longer-term risk of future generic competition or new therapies could pressure WAKIX-driven earnings.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet